liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing
Merck Sharp and Dohme Corp, NJ USA .
Merck Sharp and Dohme Corp, NJ USA .
Merck Sharp and Dohme Corp, NJ USA .
Merck Sharp and Dohme Corp, NJ USA .
Show others and affiliations
2012 (English)In: American Journal of Cardiology, ISSN 0002-9149, E-ISSN 1879-1913, Vol. 110, no 6, 817-822 p.Article in journal (Refereed) Published
Abstract [en]

Extended-release niacin (ERN) improves multiple lipid parameters but is underused owing to niacin-induced flushing (NIF). Laropiprant (LRPT) reduces NIF; however, its effects on chronic flushing (andgt;6 months) have not been studied. We examined whether after 20 weeks of treatment with ERN/LRPT, patients who continued ERN/LRPT would experience less NIF than patients who stopped LRPT and continued ERN alone. A total of 1,152 dyslipidemic patients were randomized 2:2:1 to group 1, ERN/LRPT 1 g/20 mg/day from 0 to 4 weeks and then ERN/LRPT 2 g/40 mg/day from 5 to 32 weeks; group 2, ERN/LRPT 1 g/20 mg/day from 0 to 4 weeks, ERN/LRPT 2 g/40 mg/day from 5 to 20 weeks, and then ERN 2 g/day without LRPT from 21 to 32 weeks; or group 3, placebo for the entire study. The end points included the number of days each week with a moderate or greater Global Flushing Severity Score (GFSS) andgt;= 4 (primary end point) and the percentage of patients with a maximum GFSS of andgt;= 4 (secondary end point) during the postwithdrawal period (weeks 21 to 32). ERN/LRPT produced significantly less NIF than ERN alone during the postwithdrawal period, as measured by the number of days each week with a GFSS of andgt;= 4 (p andlt; 0.001) and the percentage of patients with a maximum GFSS of andgt;= 4 (p andlt; 0.001; ERN/LRPT 19.6%; ERN 48.9%; placebo 9.2%). Compared with ERN alone, ERN/LRPT produced fewer drug-related adverse experiences during the postwithdrawal period. After 20 weeks of stable maintenance therapy, dyslipidemic patients treated continuously with ERN/LRPT experienced less NIF than did patients who had had LRPT withdrawn and had continued with ERN alone. In conclusion, the results of our study support the long-term efficacy of ERN/LRPT in reducing NIF symptoms.

Place, publisher, year, edition, pages
Elsevier , 2012. Vol. 110, no 6, 817-822 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-85092DOI: 10.1016/j.amjcard.2012.05.009ISI: 000309250300009OAI: oai:DiVA.org:liu-85092DiVA: diva2:564617
Note

Funding Agencies|Merck Sharp & Dohme, Corporation, a subsidiary of Merck & Company, Incorporated (Whitehouse Station, New Jersey)||Merck Sharp Dohme||AstraZeneca||Karo Bio||Merck||Pfizer||Roche||

Available from: 2012-11-02 Created: 2012-11-02 Last updated: 2017-12-07

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Olsson, Anders

Search in DiVA

By author/editor
Olsson, Anders
By organisation
Internal MedicineFaculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
In the same journal
American Journal of Cardiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 80 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf